NovaBridge names Martin Dewhurst as independent director

NovaBridge Biosciences (Nasdaq: NBP) said on September 8, 2026 that it had appointed Martin Dewhurst as an independent director and as a member of both the Audit Committee and the Compensation Committee, effective immediately.¹ The move coincided with a board departure: the appointment follows the exit of independent director Liu Xin, whom the company thanked for her service and contributions.¹

Dewhurst brings a long McKinsey career to the role. According to the filing, he worked at McKinsey & Company from 1992 to April 2023, during which he helped start and co-lead the McKinsey Health Institute between June 2021 and April 2023, and co-led the firm's Global Life Sciences Practice from 2014 to 2021.¹ Before that, he worked as an engagement manager at Arthur Andersen & Co. and as a marketing manager at BP Solar.¹

He also holds several outside board roles. Per the filing, he sits on the boards of Swixx BioPharma AG, Turn Therapeutics Inc. (Nasdaq: TTRX), Unilabs, Cytovation ASA and Distalmotion SA.¹ In addition, he serves on Cytovation ASA's Remuneration Committee and chairs Distalmotion SA's Audit Committee.¹ He previously held an advisory post at another life sciences firm: from April 2023 to January 2025 he chaired the Advisory Board of MedGenome Labs Ltd., and he also holds advisory or external partner positions at Revival Healthcare Capital, Lightrock and PJT Partners.¹

On education, the filing states Dewhurst holds an MBA from INSEAD and a Bachelor of Arts from Magdalen College, University of Oxford.¹

NovaBridge describes itself as a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology,¹ with its portfolio led by givastomig and VIS-101.¹